IP Library › Granted Patent US 12,221,614
Granted Patent B2
US 12,221,614 · App. 17/044,680 · Granted Feb 11, 2025

Reprogramming vectors

Inventors: Kinga Karbowniczek (Hampton, GB); Lisa Caproni (Hampton, GB); John Tite (Hampton, GB); Tristan McKay (Manchester, GB); Christopher Thornton (Manchester, GB)
Assignee: Touchlight IP Limited
C12N15/85C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608C12N2506/1307
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,614
App. No.
17/044,680
Granted
Feb 11, 2025
Kind
B2
Abstract

Reprogramming allows the “conversion” of any mature or somatic cell of the human or animal body into a pluripotent stem cell. Reprogramming can be performed through the introduction of exogenous factors, usually transcription factors, into the mature cell. This process allows the production of induced pluripotent stem cells without the use of embryos, with the advantage that they can be produced from an individual to return/re-implant to the same individual. The inventors have developed a method of transient expression of exogenous reprogramming factors using a transient vector, wherein the vector is a closed linear DNA. Surprisingly, pluripotent stem cells developed in this manner are stable and closer in phenotype to natural stem cells such as ESCs.

Claims (12)

1. A method of producing induced pluripotent stem cells (iPSCs) comprising introducing one or more closed linear vector(s) encoding one or more reprogramming factors into a population of mature somatic cells, and culturing said mature somatic cells to effect expression of the one or more reprogramming factor(s), wherein said one or more closed linear vector(s) lacks sequences for chromosomal scaffold attachment.

2. The method of claim 1 , wherein the one or more closed linear vectors includes two or more closed linear DNA vectors, each encoding one or more different reprogramming factors.

3. The method of claim 1 , wherein said reprogramming factor is selected from one or more of: Oct 3/4, Sox2, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf4, Klf5, c-myc, L-myc, and N-myc, NANOG, or LIN28.

4. The method of claim 1 , wherein said closed linear DNA vector lacks any sequence for the knockdown of p53.

5. The method of claim 1 , wherein said one or more reprogramming factors are operably linked to one or more promoters.

6. The method of claim 5 , wherein the one or more reprogramming factors are operably linked to a same promoter on the one or more closed linear vectors.

7. The method of claim 1 , wherein said one or more closed linear DNA vectors lacks one or more of:

(i) bacterial CpG motifs;

(ii) a bacterial origin of replication; or

(iii) antibiotic resistance genes.

8. The method of claim 1 , wherein said one or more closed linear vectors is a closed linear DNA vector introduced via transfection.

9. The method of claim 8 , wherein the mature somatic cells are cultured for around 30 days after transfection or nucleofection prior to reprogramming being complete.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: MCKAY, TRISTAN; THORNTON, CHRISTOPHER
To: MANCHESTER METROPOLITAN UNIVERSITY
Reel/Frame 055728/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: MANCHESTER METROPOLITAN UNIVERSITY
To: TOUCHLIGHT GENETICS LIMITED
Reel/Frame 055728/0916 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: KARBOWNICZEK, KINGA; CAPRONI, LISA JAYNE; TITE, JOHN PHILIP
To: TOUCHLIGHT GENETICS LIMITED
Reel/Frame 055728/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: TOUCHLIGHT GENETICS LIMITED
To: TOUCHLIGHT IP LIMITED
Reel/Frame 055728/0946 →
Priority Claims (1)
GB 1805683 · Apr 5, 2018 · national
Continuity (1)
Related Publication 20210147869A1 · May 20, 2021
References Cited (33)
US 20110065103A1 · Sahin · 2011 [cited by examiner]
JP 2011505814A · 2011 [cited by applicant]
WO WO2009077134A2 · 2009 [cited by applicant]
WO WO2010086626A1 · 2010 [cited by applicant]
WO WO2012017210A1 · 2012 [cited by applicant]
WO WO2016132129A1 · 2016 [cited by applicant]
WO WO2016195598A1 · 2016 [cited by applicant]
Narsihn et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors (2011) Nature Protocols, 6, pp. 78-88. (Year: 2011). [cited by examiner]
Nafissi et al. Construction and Characterization of an in-vivo Linear Covalently Closed DNA Vector Production System (2012) Microbial Cell Factories, 11, pp. 1-13. (Year: 2012). [cited by examiner]
Okita et al. A more efficient method to generate integration-free human iPS cells (2011) Nature Methods, 8, pp. 409-412 (Year: 2011). [cited by examiner]
Nafissi, N. et al., “Construction and Characterization of an in-vivo Linear Covalently Closed DNA Vector Production System”, Microbial Cell Factories, vol. 11, pp. 1-13 (Dec. 2012). [cited by applicant]
Wong, S. et al., “DNA Ministrings: Linear-Covalently Closed Minivectors for Use in Non-Viral Gene Therapy with Applications Toward Ovarian Cancer,” Molecular Therapy, vol. 23, Sppl 1, pp. 5229-5230 (2015). [cited by applicant]
Wong, S. et al., “Production Double-stranded DNA Ministrings”, Journal of Visualised Experiments, vol. 108, article No. e53177 (2016). [cited by applicant]
Wong, S. et al., “Optimizations in the Production of DNA Ministrings, Linear-Covalently Closed DNA Minivectors for Use in Non-Viral Gene Therapy,” Molecular Therapy, vol. 25, No. 5, p. 358 (2017). [cited by applicant]
Nafissi, N. et al., “DNA Ministrings: Highly Safe and Effective Gene Delivery Vectors,” Molecular Therapy Nucleic Acids, vol. 3, No. 6, article No. e165 (2014). [cited by applicant]
Schakowski, F. et al., “Minimal Size MIDGE Vectors Improve Transgene Expression In Vivo,” In Vivo, vol. 21, No. 1, pp. 17-23 (2007). [cited by applicant]
Kobelt, D. et al., “Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGEDNA vector,” Molecular Oncology, vol. 8, pp. 609-619 (2014). [cited by applicant]
Walther, W. et al., “Improved transfer efficiency and transgene expression in vitro and in vivo using the minimalistic nonviral MIDGE expression system,” AACR—Annual Meeting Apr. 18-22, 2009, vol. 69, No. 9, Suppl, abst… [cited by applicant]
Mok, P.L. et al., “In vitro expression of erythropoietin by transfected human mesenchymal stromal cells,” Cytotherapy, vol. 10, No. 2, pp. 116-124 (2008). [cited by applicant]
Hu et al., “Generation of Hypoimmunogenic Induced Pluripotent Stem Cells for Allogeneic Cell and Tissue Transplantation”, Thoracic and Cardiovascular Surgeon, vol. 66, Supp. 1, Jan. 2018. [cited by applicant]
Yu et al., “Nonviral minicircle generation of induced pluripotent stem cells compatible with production of chimeric chickens”, Cell Reprogram, vol. 16, No. 5, pp. 366-378, Oct. 2014. [cited by applicant]
Andrews, P.W. et al., “Induction of Class I Major Histocompatibility Complex Antigens in Teratocarcinoma Cells by Interferon without Induction of Differentiation, Growth Inhibition, or Resistance to Viral Infection,” Ca… [cited by applicant]
Eggenberger, J. et al., “Type I interferon response impairs differentiation potential of pluripotent stem cells,” PNAS, vol. 116, pp. 1384-1393 (2019). [cited by applicant]
Henderson, J.K. et al., “Preimplantation Human Embryos and Embryonic Stem Cells Show Comparable Expression of Stage-Specific Embryonic Antigens,” Stem Cells, vol. 20, pp. 329-337 (2002). [cited by applicant]
International Search Report in International Application No. PCT/GB2019/051000, mailed Jul. 31, 2019 (5 pages). [cited by applicant]
Isogai, S. et al., “Preparation of Induced Pluripotent Stem Cells Using Human Peripheral Blood Monocytes,” [cited by applicant]
Nafissi, N., “Construction and Characterization of a Robust in vivo Technology for the Production of Superior DNA Vectors with Applications in Gene Therapy and Vaccine Development,” Ph.D. Thesis, University of Waterloo,… [cited by applicant]
Nanbo, A. et al., “The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells,” [cited by applicant]
Narsinh, K.H. et al., “Generation of Adult Human Induced Pluripotent Stem Cells Using Non-Viral Minicircle DNA vectors,” [cited by applicant]
Takahashi, K. et al., “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” [cited by applicant]
Yu, J. et al., “Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences,” [cited by applicant]
Zhou, T. et al., “Generation of human induced pluripotent stem cells from urine samples,” [cited by applicant]
Zhou, Y-Y. et al., “Integration-free Methods for Generating Induced Pluripotent Stem Cells,” [cited by applicant]